The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Less commonly observed toxicities following CAR T-cell therapy
In this video, Veronika Bachanova, MD, PhD, University of Minnesota, Minneapolis, MN, outlines less commonly observed toxicities following CAR T-cell therapy, such as immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Dr Bachanova also notes the significance of cytopenias and infections and emphasizes the importance of preventing complications by treating patients with prophylactic antimicrobial therapies and growth factor support. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In addition to the known immune effect toxicities such as CRS and ICANS, there is indeed the increasing recognition of some additional things such as immune effector HLH-like syndrome. I think it’s really underdiagnosed and underreported in the registries and also real-world analyses just because it has to be looked for actively and diagnosed with a very precise focus on understanding and taking the particular lab results such as ferritin levels sequentially over a period of hours, two days...
In addition to the known immune effect toxicities such as CRS and ICANS, there is indeed the increasing recognition of some additional things such as immune effector HLH-like syndrome. I think it’s really underdiagnosed and underreported in the registries and also real-world analyses just because it has to be looked for actively and diagnosed with a very precise focus on understanding and taking the particular lab results such as ferritin levels sequentially over a period of hours, two days.
The other toxicity which I think is very important is cytopenias and subsequent risk for infections. We now know that the most significant mortality is due to infections. So I think as a clinician looking to improve outcomes, I’m very aware of the monitoring for the delayed cytopenias, managing them, preventing the complications by using patients on prophylactic antimicrobial and antifungal therapies, but also really treating them with the growth factor support.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
